HomeCompareBNPJY vs JNJ

BNPJY vs JNJ: Dividend Comparison 2026

BNPJY yields 6.37% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNPJY wins by $25105.82M in total portfolio value
10 years
BNPJY
BNPJY
● Live price
6.37%
Share price
$1.60
Annual div
$0.10
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25105.85M
Annual income
$24,370,393,261.15
Full BNPJY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BNPJY vs JNJ

📍 BNPJY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNPJYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNPJY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNPJY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNPJY
Annual income on $10K today (after 15% tax)
$541.08/yr
After 10yr DRIP, annual income (after tax)
$20,714,834,271.98/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, BNPJY beats the other by $20,714,830,285.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNPJY + JNJ for your $10,000?

BNPJY: 50%JNJ: 50%
100% JNJ50/50100% BNPJY
Portfolio after 10yr
$12552.94M
Annual income
$12,185,198,975.27/yr
Blended yield
97.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BNPJY
No analyst data
Altman Z
0.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNPJY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNPJYJNJ
Forward yield6.37%2.13%
Annual dividend / share$0.10$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$25105.85M$30.3K
Annual income after 10y$24,370,393,261.15$4,689.40
Total dividends collected$25055.07M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BNPJY vs JNJ ($10,000, DRIP)

YearBNPJY PortfolioBNPJY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,973$1,273.13$10,592$272.30+$1.4KBNPJY
2$15,660$2,849.21$11,289$357.73+$4.4KBNPJY
3$23,722$6,965.75$12,123$472.89+$11.6KBNPJY
4$45,106$19,722.82$13,141$629.86+$32.0KBNPJY
5$118,358$70,095.25$14,408$846.81+$104.0KBNPJY
6$470,440$343,796.57$16,021$1,151.60+$454.4KBNPJY
7$3,057,558$2,554,187.24$18,122$1,588.22+$3.04MBNPJY
8$34,300,696$31,029,108.98$20,930$2,228.20+$34.28MBNPJY
9$687,346,189$650,644,444.28$24,792$3,191.91+$687.32MBNPJY
10$25,105,853,684$24,370,393,261.15$30,274$4,689.40+$25105.82MBNPJY

BNPJY vs JNJ: Complete Analysis 2026

BNPJYStock

Banpu Public Company Limited engages in the coal mining and power businesses. It holds 50% interest in a 1,434 MW coal-fired power plant in Map Ta Phut Industrial Estate, Rayong Province, Thailand; and 100% interest in Temple 1 gas-fired power plant with a generation capacity of 768 MW located in Texas, the United States. The company also manages five coal mines in Kalimantan comprising Indominco, Jorong, Kitadin-Embalut, Trubaindo, and Bharinto, which produce a range of bituminous and sub-bituminous thermal coals in Indonesia. In addition, it operates the Gaohe coal mine in Shanxi Province and Hebi mine in Henan Province; operates and manages 3 coal-fired combined heat and power plants with a capacity of 539 megawatts in China; and owns various coal mines located in New South Wales, Australia. Further, the company operates various coal project in Mongolia; thermal power plants in Lao PDR; wind farm in Vietnam; and solar farms in Japan. Additionally, it provides solar rooftop solutions and installation for industries and large businesses; energy storage solutions; electric vehicle and fleet management services; consultation services on customized energy management system; and renewable energy ecosystem for clean energy. The company also involved in the power and steam production, purchase, and trading business; provident fund management; solar power generation; logistics; sales and marketing activities; natural gas business; investment in power and renewable energy; and research and development business. It also provides coal mining and trading; and business consultancy services, as well as fuel trading services. The company was formerly known as Ban Pu Coal Company Limited and changed its name to Banpu Public Company Limited in July 1993. Banpu Public Company Limited was founded in 1983 and is headquartered in Bangkok, Thailand.

Full BNPJY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BNPJY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNPJY vs SCHDBNPJY vs JEPIBNPJY vs OBNPJY vs KOBNPJY vs MAINBNPJY vs ABBVBNPJY vs MRKBNPJY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.